Core Viewpoint - Hanbang Technology (688755.SH) is set to launch its IPO on May 7, 2023, with a price of 22.77 yuan per share, which corresponds to a P/E ratio of 26.35, slightly below the industry average of 28.04 and the comparable companies' average of 46.64 [1] Company Overview - Hanbang Technology, established in October 1998, focuses on chromatography technology, providing specialized separation and purification equipment, consumables, and technical solutions for the pharmaceutical and life sciences sectors [3] - The company aims to raise approximately 5.01 billion yuan through the issuance of 22 million shares, with a net fundraising amount expected to be around 4.31 billion yuan after deducting issuance costs [1] Financial Performance - Revenue for Hanbang Technology is projected to grow from 482 million yuan in 2022 to 691 million yuan in 2024, with net profits increasing from approximately 38.56 million yuan to 79.34 million yuan during the same period [3][4] - The gross profit margin is expected to improve from 39.22% in 2022 to 42.46% in 2024 [3] - The company's total assets are projected to decrease from 1.40 billion yuan in 2022 to 1.32 billion yuan in 2024, while the equity attributable to shareholders is expected to rise from 566.92 million yuan to 739.63 million yuan [4] Revenue Composition - The primary revenue sources for Hanbang Technology are small molecule and large molecule drug separation and purification equipment, with small molecule equipment sales increasing from 49.75% of revenue in 2022 to 66.7% in 2024 [5][6] - The revenue from large molecule drug separation equipment is expected to decline from 44.46% in 2022 to 28% in 2024 [6] R&D and Accounts Receivable - R&D expenditures for Hanbang Technology were 28.99 million yuan, 37.18 million yuan, and 41.84 million yuan over the last three years, totaling 108 million yuan, which is 6.03% of cumulative revenue [8] - The accounts receivable at the end of the reporting periods were 131 million yuan, 119 million yuan, and 130 million yuan, with overdue accounts receivable making up a significant portion [8] Market Position and Risks - Hanbang Technology holds the leading market share in the domestic small molecule liquid chromatography system market, reaching 39.2% in 2023, but faces limited room for further growth [9] - The company is involved in ongoing patent infringement lawsuits with Cytiva, which could negatively impact its financial performance if the rulings are unfavorable [9]

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. has officially launched its initial public offering (IPO) process, with the online and offline subscription date set for May 7, 2025 [1] Company Overview - Hanbang Technology is a high-tech enterprise focused on chromatography technology, providing specialized separation and purification equipment, consumables, application technology services, and related technical solutions primarily for the pharmaceutical and life sciences sectors [2][3] - The company is one of the earliest domestic manufacturers with complete independent intellectual property rights for liquid chromatography systems, breaking the long-standing foreign monopoly in related technologies and products [2] Market Position - According to Frost & Sullivan, the total market size for liquid chromatography equipment in China exceeded 2.7 billion yuan in 2023, with Hanbang Technology ranking second in the production-grade liquid chromatography separation equipment market, holding a market share of approximately 12.7% [2] - In the production-grade small molecule liquid chromatography system market, Hanbang Technology achieved a market share of 39.2% in a market size of approximately 780 million yuan in 2023 [2] - The company ranked third in the production-grade macromolecule chromatography system market, with a market share of about 8.8% in a market size of approximately 2.5 billion yuan in 2023 [2] Industry Growth Drivers - The chromatography equipment market is expanding globally, particularly in China, driven by the continuous development of application fields, domestic substitution, and rapid growth in downstream industries [3] - Since 2021, various national policies and regulations have been introduced to support the development of the pharmaceutical and scientific instrument sectors, creating a favorable operating environment for companies like Hanbang Technology [3] Financial Performance - Hanbang Technology's revenue has shown consistent growth from 321 million yuan in 2021 to an estimated 691 million yuan in 2024, while net profit attributable to shareholders increased from 4.86 million yuan to approximately 79.34 million yuan during the same period [3] R&D and Technological Strength - The company has focused on chromatography separation and purification products for nearly 30 years, with R&D investment increasing from 22.04 million yuan in 2021 to 41.84 million yuan in 2024 [4] - Hanbang Technology has developed several core technologies and holds 53 authorized invention patents, including 40 domestic and 13 overseas patents [4] IPO Fund Utilization - The funds raised from the IPO will be used to expand and deepen existing business operations, including projects for producing 1,000 units of liquid chromatography separation equipment, establishing a chromatography separation equipment R&D center, and producing 2,000 units of laboratory chromatography purification instruments [5][6]